KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Current Investments (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Cash & Current Investments data on record, last reported at $2.7 billion in Q1 2025.

  • For Q1 2025, Cash & Current Investments rose 2511.02% year-over-year to $2.7 billion; the TTM value through Mar 2025 reached $2.7 billion, changed N/A, while the annual FY2025 figure was $2.7 billion, 2444.83% up from the prior year.
  • Cash & Current Investments reached $2.7 billion in Q1 2025 per TAK's latest filing, up from $101.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $9.5 billion in Q1 2021 and bottomed at $101.8 million in Q1 2024.
  • Average Cash & Current Investments over 5 years is $4.7 billion, with a median of $4.0 billion recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: plummeted 97.48% in 2024, then surged 2511.02% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $9.5 billion in 2021, then decreased by 22.83% to $7.3 billion in 2022, then plummeted by 44.83% to $4.0 billion in 2023, then plummeted by 97.48% to $101.8 million in 2024, then skyrocketed by 2511.02% to $2.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $2.7 billion in Q1 2025, $101.8 million in Q1 2024, and $4.0 billion in Q1 2023.